ProCE Banner Activity

Identifying and Mitigating Adverse Events Associated With ALK Inhibitors for Advanced ALK-Positive Non-Small-Cell Lung Cancer

PDF

This short downloadable PDF lists key adverse events that may occur in patients with advanced ALK-positive NSCLC who are receiving ALK inhibitors. Management recommendations are also provided.

Released: April 04, 2025

Expiration: October 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Todd M. Bauer, MD: consultant/advisor/speaker: Bayer, FMI, Pfizer, Tempus.

Christine Bestvina, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Genentech, Gilead, Guardant, Johnson & Johnson, Mirati, Novocure, Pfizer, Sanofi, Tempus, Turning Point Therapeutics; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb; other financial or material support: AstraZeneca, Bristol Myers Squibb, Guardant, Johnson & Johnson.

Jessica J. Lin, MD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, Claim Therapeutics, Daiichi Sankyo, Elevation Oncology, Ellipses, Genentech, Gilead, Janssen, Lilly, Merus, Mirtati Therapeutics, Novartis, Nuvation Bio, Nuvalent, Pfizer, Regeneron, Roche, Takeda, Turing Point Therapeutics, Yuhan; researcher (paid to institution): Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Novartis, Nuvalent, Roche, Relay Therapeutics, Turning Point Therapeutics; other (travel support): Bristol Myers Squibb, Merus, Pfizer, Takeda.

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Jazz, Lilly, Merck, Pfizer, Takeda.